Syros Pharmaceuticals, Inc. (SYRS) has 43 open-market insider trades by 21 insiders since 2016. The most active filer is Richard A. Young, Director.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Srinivas Akkaraju | Dir | — | 7 | $21.0M | 2024-09-16 |
| Amir Nashat | Dir10% Owner | — | 1 | $10.0M | 2016-07-06 |
| Jeremy Green | 10% Owner | — | 2 | $7.3M | 2016-07-06 |
| James E. Flynn | 10% Owner | — | 1 | $5.0M | 2016-07-06 |
| Robert Nelsen | Dir10% Owner | — | 1 | $5.0M | 2016-07-06 |
| Flagship Ventures Fund IV, L.P. | 10% Owner | — | 1 | $5.0M | 2016-07-06 |
| Clinton Bybee | 10% Owner | — | 1 | $5.0M | 2016-07-06 |
| Polaris Partners VII, L.P. | 10% Owner | — | 1 | $5.0M | 2016-07-06 |
| ARCH Venture Fund VII, L.P. | 10% Owner | — | 2 | $4.5M | 2019-03-14 |
| ARCH Venture Partners VII, L.P. | 10% Owner | — | 1 | $957K | 2019-07-17 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Nancy A. Simonian | Director | Sell | $10K | 2024-12-02 |
| Nancy A. Simonian | Director | Sell | $36K | 2024-11-25 |
| Gerald E. Quirk | Chief Legal & Compliance Offic | Sell | $10K | 2024-11-19 |
| Kristin Stephens | Chief Development Officer | Sell | $8K | 2024-11-18 |
| Conley Chee | President | Sell | $27K | 2024-11-18 |
| David Roth | Chief Medical Officer | Sell | $2K |
Companies that share insiders with SYRS, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| 2024-11-18 |
| Jason Haas | CFO | Sell | $29K | 2024-11-18 |
| Jason Haas | CFO | Buy | $292K | 2024-09-10 |
| Conley Chee | CEO & President | Buy | $161K | 2024-09-10 |
| Richard A. Young | Director | Sell | $357K | 2024-06-28 |
| David Roth | — | Sell | $103K | 2024-04-03 |
| David Roth | Chief Medical Officer | Sell | $747 | 2024-04-02 |
| Srinivas Akkaraju | Director | Buy | $8.0M | 2023-12-21 |
| David Roth | Chief Medical Officer | Sell | $31K | 2023-12-12 |
| David Roth | Chief Medical Officer | Sell | $25K | 2023-12-06 |